Fulcrum Therapeutics, Inc.FULCEarnings & Financial Report
Nasdaq
NextMar 13, 2026
FULC Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-21.9M
Net Profit
$-19.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.31
Fulcrum Therapeutics, Inc. Q3 2025 Financial Summary
Fulcrum Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-19.6M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-19.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Fulcrum Therapeutics, Inc. Annual Revenue by Year
Fulcrum Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $80.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $80.0M |
| 2023 | $2.8M |
| 2022 | $6.3M |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $759000 | $871000 | $0 | $80.0M | $0 | $0 | $0 | $0 |
| YoY Growth | -35.8% | 27.2% | N/A | 8990.9% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $278.9M | $257.7M | $232.6M | $294.3M | $279.0M | $260.7M | $228.8M | $214.9M |
| Liabilities | $23.4M | $22.5M | $19.0M | $20.5M | $21.7M | $17.7M | $14.5M | $16.5M |
| Equity | $255.5M | $235.2M | $213.6M | $273.8M | $257.3M | $243.0M | $214.4M | $198.4M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.9M | $-23.2M | $-25.3M | $58.9M | $-19.1M | $-16.8M | $-13.8M | $-14.2M |